Search

Learn about the latest research on why more young adults are developing cancer, from investigators across MSK.

… Monday, January 5, 2026 It’s a disturbing mystery that has drawn the attention of investigators from across Memorial Sloan Kettering Cancer Center (MSK). Why are a growing number of young people under 50 being diagnosed with over a dozen forms of cancer around the world? This trend is especially worrying

Obtenga las últimas actualizaciones de investigación de investigadores de MSK sobre por qué tantos adultos jóvenes tienen cáncer.

… Monday, January 5, 2026 Es un misterio inquietante que ha llamado la atención de los investigadores de todo Memorial Sloan Kettering Cancer Center (MSK). ¿Por qué cada vez más se diagnostica a jóvenes menores de 50 años con más de una decena de formas de cáncer en todo el mundo? Esta tendencia es especialmente

Analysis of long-preserved single cells on pathology slides aims to provide new clues about the genes that make breast cancer more aggressive.

… Friday, February 10, 2017 Summary A new technique that enables researchers to study single cells from older samples taken from people with breast cancer is opening the door to new findings about genetic changes that make cancer aggressive. Highlights MSK has an incredible storehouse of tumor samples

Scientists have learned that cutting a T cell’s brakes can have unexpected consequences.

… Monday, June 17, 2019 Summary Scientists at the Sloan Kettering Institute have discovered that a particular protein controls whether an immune cell makes braking molecules, such as PD-1. Immune cells lacking this protein behave in an unexpected way. The 2018 Nobel Prize in Physiology or Medicine went

A collaborative team of leaders in the field of cancer immunology has made a key discovery that advances the understanding of why some patients respond to ipilimumab, an immunotherapy drug, while others do not.

… Wednesday, November 19, 2014 A collaborative team of leaders in the field of cancer immunology from Memorial Sloan Kettering Cancer Center has made a key discovery that advances the understanding of why some patients respond to ipilimumab, an immunotherapy drug, while others do not.  MSK was at the forefront

Memorial Sloan Kettering endocrinologist Azeez Farooki discusses the risk factors associated with diabetes and why cancer treatment may be more complicated for those who are diabetic.

… Tuesday, November 26, 2013 Summary Memorial Sloan Kettering endocrinologist Azeez Farooki discusses the risk factors associated with diabetes and why cancer treatment may be more complicated for those who are diabetic. More than 25 million people in the United States have been diagnosed with diabetes

New MSK research highlights the importance of tumor location in metastasis; shows how regulatory T cells work with sensory nerves in the skin to restrain pain and inflammation; explores whether a large language model can adequately summarize cancer patients’ experiences with pain; and finds proton therapy is effective at treating leptomeningeal metastasis.

… Thursday, September 25, 2025 New research from Memorial Sloan Kettering Cancer Center (MSK) highlights the importance of tumor location in metastasis; shows how regulatory T cells work with sensory nerves in the skin to restrain pain and inflammation; explores whether a large language model can adequately

To explore new treatment options – and potentially change the standard of care for resected lung cancer – Memorial Sloan Kettering Cancer Center is enrolling patients in a National Cancer Institute-sponsored trial.

… Friday, September 23, 2016 Memorial Sloan Kettering Cancer Center is proud to be participating in the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). ALCHEMIST is a large, multicenter trial sponsored by the National Cancer Institute to assess newly available and

Sloan Kettering Institute Director Thomas J. Kelly has been named a member of the Advisory Committee to the Director (ACD) at the National Institutes of Health.

… Thursday, May 1, 2008 Summary Sloan Kettering Institute Director Thomas J. Kelly has been named a member of the Advisory Committee to the Director (ACD) at the National Institutes of Health. Sloan Kettering Institute Director Thomas J. Kelly has been named a member of the Advisory Committee to the Director

During the early days of the COVID-19 outbreak, a team of radiation oncologists specializing in breast cancer management at Memorial Sloan Kettering Cancer Center reviewed the literature and established recommendations for the safe use of hypofractionated and abbreviated radiation regimens for our patients with breast cancer.

… Monday, May 11, 2020 As governments and health authorities restrict in-person interactions to contain the spread of COVID-19, radiation oncologists must make unprecedented decisions on behalf of patients needing radiotherapy. We must balance the risk of presenting for treatment with being exposed to